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Abstract
Background: Activated leukocyte cell adhesion molecule (ALCAM/CD166) is expressed by hematopoietic stem
cells. However, its role in hematopoietic differentiation has not previously been defined.
Results: In this study, we show that ALCAM expression is silenced in erythromegakaryocytic progenitor cell lines. In
agreement with this finding, the ALCAM promoter is occupied by GATA-1 in vivo, and a cognate motif at -850
inhibited promoter activity in K562 and MEG-01 cells. Gain-of-function studies showed that ALCAM clusters K562
cells in a process that requires PKC. Induction of megakaryocytic differentiation in K562 clones expressing ALCAM
activated PKC-δ and triggered apoptosis.
Conclusions: There is a lineage-specific silencing of ALCAM in bi-potential erythromegakaryocytic progenitor cell
lines. Marked apoptosis of ALCAM-expressing K562 clones treated with PMA suggests that aberrant ALCAM
expression in erythromegakaryocytic progenitors may contribute to megakaryocytopenia.
Background
Hematopoiesis is controlled by interactions between
hematopoietic stem cells and their microenvironment.
These interactions influence retention of stem cells in
specific niches, and stem and progenitor cell expansion,
lineage divergence and differentiation [1]. Adhesion
molecules are major regulators of cell-cell interactions
and they influence multiple aspects of hematopoiesis
[1-4]. Indeed, antibodies against various adhesion mole-
cules including VLA-4 and VCAM-1 inhibit the ability
of hematopoietic stem cells to populate the bone mar-
row of irradiated mice [5], and gene knock-out studies
of integrins have shown their critical role in homing and
colonization of late-stage primary hematopoietic organs
such as the embryonic liver [6,7]. More recently,
N-cadherin expression has been implicated in retention
of hematopoietic stem cells in the bone marrow niche
[8-10] although this claim is not supported by other stu-
dies [11]. In contrast to their role in homing, our under-
standing of adhesion molecule biology in lineage
commitment and differentiation is poorly defined.
Hematopoietic cell antigen, also known as activated
leukocyte cell adhesion molecule (ALCAM/CD166), is a
member of the immunoglobulin super-family. It is
expressed on the surface of the most primitive hemato-
poietic cells in human fetal liver and fetal and adult
bone marrow [12]. Other studies have found ALCAM
expression on subsets of stromal cells in the para-aortic
mesoderm and other primary sites of hematopoiesis in
the human embryo [13]. ALCAM-mediated interactions
are important during neural development [14], matura-
tion of hematopoietic stem cells in blood forming tis-
sues [12,15], immune responses [16] and in tumor
progression [17]. Anti-ALCAM antibodies inhibit mye-
loid colony formation in vitro by mechanism that
remains unknown [18]. We showed previously that
ALCAM is involved in transmigration of monocytes
across endothelial monolayers [19]. More recent in vivo
studies have shown that ALCAM is essential for mono-
cyte migration across the blood-brain barrier [20]. Other
studies indicate the interaction of ALCAM on dendritic
cells with the T-cell ligand CD6 is required for optimal
T-cell activation [21]. While these studies highlight
ALCAM’s role in mature and activated leukocyte cell
biology, there is currently no information on ALCAM’s
role in hematopoietic progenitor cell biology.
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human hematopoietic cell lines. The ALCAM gene was
cloned and functionally characterized in K562 cell lines.
The influence of ALCAM on megakaryocytic differentia-
tion of K562 cells was investigated.
Results
Lineage-specific expression of ALCAM in hematopoietic
progenitor cell lines
Previous studies have documented ALCAM surface
expression on hematopoietic stem and progenitor cells.
In this study, we quantified ALCAM mRNA expression
in multiple human hematopoietic progenitor cell lines of
myeloid, lymphoid, erythroid, and megakaryocytic
lineages by real-time quantitative PCR. ALCAM mRNA
was most abundant in THP-1 monocytes, at a level
2-fold higher than in HL-60 cells, and 8-fold higher
than in U-937 and Jurkat cells (Figure 1A). No ALCAM
transcripts were however detected in K562 and MEG-01
cells (Figure 1A). This expression pattern was confirmed
at the protein level as none of the erythromegakaryocy-
tic progenitor cell lines (K562, MEG-01) expressed
ALCAM, while ALCAM protein was abundant in
THP-1 monocytes (Figure 1B).
A negative GATA-1 binding element in the
ALCAM promoter
Thus far, we had identified an expression pattern for
ALCAM that was consistent with regulation of the
ALCAM gene by erythroid and megakaryocytic tran-
scription factors. To investigate this idea, multiple frag-
ments of the ALCAM 5’-flanking region was cloned,
sequenced and its activity analyzed in K562 and MEG-
01 cells. Activity of the p650 construct was on average
4 0 - f o l dh i g h e rc o m p a r e dt op G L 3i nb o t hc e l lt y p e s
(Figure 2A). Activity of p1000 was significantly lower
compared to p800, which suggested the presence of
negative regulatory cis element in the interval -800 to
-1000 of the ALCAM gene. Sequence analysis using the
TRANSFAC 7.0 software identified a GATA-1 motif at
-850. Mutation of this cis element increased activity of
p1000 by 3-fold (Figure 2B). To confirm a role for
GATA-1, K562 nuclear extracts were used in gel mobi-
lity shift assay. A single major protein-DNA complex
formed on a -850 ALCAM DNA probe using nuclear
extracts from K562 and MEG-01 cells (Figure 2C, lane 2
and data not shown). Formation of this complex was
competitively blocked by unlabeled wild-type -850
ALCAM GATA probe indicating the specificity of this
cis element in the protein-DNA complex (lanes 3-5),
and by anti-GATA-1 antibody (lane 6), which confirmed
that the GATA-1 protein is a component of this pro-
tein-DNA complex. On the contrary, increasing molar
excess of an unlabeled mutant -850 ALCAM probe
failed to compete for binding (lanes 7-9). Finally, we
prepared chromatin from K562 cells to determine
whether GATA-1 occupied the ALCAM promoter in
vivo. Results of ChIP assay experiments confirmed that
GATA-1 binds to the endogenous promoter in K562
cells (Figure 2D). Collectively, these findings suggest
that ALCAM silencing is part of the mechanism of
GATA-1 mediated megakaryocytic differentiation.
Ectopic ALCAM expression clusters K562 cells in a PKC-
dependant manner
To determine the functional relevance of ALCAM silen-
cing, we established clones of K562 stably expressing
ALCAM linked to a green florescent protein (K562-
ALCAM) or a GFP vector (K562). ALCAM was abun-
dantly expressed in these stable K562 clones while it
was absent in the control clones expressing GFP (Figure
3A). Live-cell imaging showed that ALCAM was
recruited to sites of cell-cell contact in the K562-
ALCAM clones whereas GFP remained distributed in
the cytosol in the control K562-GFP clones (Figure 3B).
Unlike parental K562 and K562-GFP clones, the K562-
ALCAM clones consistently formed large clusters in
culture, spontaneously. To test whether ALCAM is
responsible for this behavior, a function blocking anti-
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Figure 1 ALCAM expression in hematopoietic progenitor cell
lines. A) Total RNA was isolated from hematopoietic cells and
ALCAM mRNA quantified by quantitative RT-PCR. GAPDH was used
as invariant control in the experiment. Data shown is the mean of
three analyses each in triplicates. B) Whole cell lysates (15 μg) from
indicated cells were blotted for ALCAM protein by western blot
analysis and protein loading verified by analyzing the same filters
for EF-1a expression.
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Figure 2 A functional GATA-1 element in the proximal ALCAM promoter. A) Schematic diagram of reporter constructs consisting of
truncated ALCAM promoter fragments driving expression of pGL3. Histogram shows the relative luciferase activity for each construct in K562
and MEG-01 cells. B) Reporter constructs showing the presence of wild-type (filled circle) or mutant (open circle) GATA-1 cis element at -850 in
the human ALCAM promoter. Histogram shows the relative luciferase activity for each construct in K562 and MEG-01 cells. C) Electrophoretic
mobility shift assay showing protein-DNA complexes in experiments performed with the -850 GATA probe and no nuclear extracts (lane 1), or
with K562 nuclear extracts alone (lane 2), and in the presence of molar excess of unlabeled wild-type probe (lanes 3-5), anti-GATA1 antibody
(lane 6) and unlabeled mutant -850 GATA1 probe (lanes 7-9). D) Ethidium bromide stained gel of ChIP assay PCR products showing a 151 bp
product for input DNA (lane 2), and products from chromatin immunoprecipitations performed with anti-GATA1 antibody (lane 3), IgG (lane 4)
and without chromatin (lane 5). Lane 1 contains DNA size marker.
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Page 3 of 12ALCAM antibody that we and others have shown
previously to inhibit ALCAM-mediated homotypic adhe-
sion was added to cultures. Anti-ALCAM antibody
(10 μg/ml) prevented cell clustering whereas an isotype-
matched IgG had no effect (Figure 3C). Moreover,
anti-ALCAM antibody disaggregated pre-formed K562-
ALCAM clusters while isotype-matched IgG had no
impact (Figure 3D). PKC-a has previously been impli-
cated in ALCAM-mediated cytoskeletal alterations in
K562 cells, therefore we tested whether this mediator
was involved in ALCAM-induced K562 clustering. Inhi-
bition of PKC dose-dependently blocked clustering of
K562-ALCAM cells, while DMSO had no impact on
this behavior (Figure 4A). Moreover, the pan-PKC
inhibitor chelerythrine chloride dose-dependently disag-
gregated previously formed large aggregates of K562-
ALCAM cells (Figure 4B). These data indicate that PKC
contributes to the ALCAM-mediated aggregation of
hematopoietic cells.
To analyze the PKC mechanisms involved in ALCAM-
mediated cell clustering, we examined expression of
PKC isoforms by qRT-PCR. There was significantly
increased expression of PKC-a, but not of PKC-δ,- ε or
-θ in these cells at baseline. The level of PKC-a mRNA
was 3-fold higher in K562-ALCAM clones than in
control cells (Figure 5A). The pan-PKC activator PMA
significantly increased mRNA expression of three iso-
forms (a, ε and θ) in both K562-ALCAM and the con-
trol K562-GFP cells (Figure 5A). PKC-δ mRNA
expression increased significantly in the K562-ALCAM
clones, but not in control cells. Next, we examined
steady-state and PMA-induced levels and activation of
PKC-a and PKC-δ.T h el e v e lo fP K C - a protein was
increased in K562-ALCAM clones, at steady-state and
following PMA treatment, however PMA did not
increase activation of PKC-a (Figure 5B, C). On the
contrary, PMA activated PKC-δ in the K562-ALCAM
clones, while the activation status in control cells
remained unchanged (Figure 5B, C).
Altered erythromegakaryocytic gene expression in
K562-ALCAM clones
K562 is an established model for megakaryocytic differ-
entiation in a process that is PKC-ε dependent [22,23].
Thus our data showing that ectopic expression of
ALCAM in K562 cells increasede x p r e s s i o na n da c t i v a -
tion of PKC-a, suggested that the normal megakaryocy-
tic pathway may be altered in these clones. Transcripts
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Figure 3 Ectopic expression of ALCAM clusters K562 cells.
A) Western blot analysis shows expression of ALCAM in K562 clones
stably transfected with ALCAM-GFP (#1, #2), but not in clones
transfected with empty vector (#15, #16). B) Live-cell imaging of
K562-ALCAM (#1) and control K562 (#15) clones. C)
Photomicrographs of K562-ALCAM cells seeded with anti-ALCAM
anti-body or IgG and cultured for 24 hours. Note formation of a
large aggregate of cells in cultures containing IgG. D)
Photomicrographs of pre-formed K562-ALCAM cell clusters treated
with anti-ALCAM antibody or IgG for 24 hours. Anti-ALCAM
antibody disaggregates cell clusters while IGg has no impact.
A
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Figure 4 ALCAM-induced clustering of K562 cells is PKC-
dependant. A) Photomicrographs of K562-ALCAM single cell
suspensions treated with a concentration (5-20 μM) range of
chelerythrine chloride or DMSO (vehicle) at the time of seeding (0
hr) and 24 hours later. Chelerythrine chloride dose-dependently
inhibits the formation of clusters of K562-ALCAM. B)
Photomicrographs of preformed K562-ALCAM clusters treated with
a concentration (5-20 μM) range of chelerythrine chloride or DMSO
(vehicle). Chelerythrine chloride dose-dependently disaggregates
pre-formed clusters. Cultures were photographed using Olympus
IX50 microscope (Olympus Optical Co. Ltd. Japan).
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Figure 5 ALCAM alters expression of PKC in K562 cells. A) Quantification of PKC mRNA level in K562-ALCAM (#1, #2) and K562 (#15) clones
at steady-state (vehicle) and following treatment with 20 nM PMA for 48 h. B) Western blot analysis showing expression of the indicated
proteins in control K562 clone #15 (lanes 1, 4), ALCAM-expressing clones #1(lane 2, 5) and #2 (lanes 3, 6) at steady-state (-) and following
treatment with PMA (+). C) Quantification of PKCa and PKCδ activation.
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Figure 6 Profile of PMA-induced gene expression in K562 cells is altered by ALCAM. Quantification of mRNA for; A) PKC-inducible gene
CD44, B) megakaryocytic genes, CD61 and c-Mpl, and C) erythroid genes, glycophorin A and g-globulin, in K562-ALCAM (#1, #2) and K562 (#15)
at steady-state and following treatment with 20 nM PMA for 48 h.
Tan et al. BMC Molecular Biology 2010, 11:91
http://www.biomedcentral.com/1471-2199/11/91
Page 6 of 12for the PMA-inducible gene CD44 was greater than
10-fold higher in the K562-ALCAM clones compared to
control K562 cells at baseline, while PMA increased its
expression 3 to 5-fold higher in K562-ALCAM clones
compared to control K562 cells (Figure 6A). With
respect to hematopoietic genes, transcripts for the
megakaryocytic marker CD61 was 3-10 fold higher in
K562-ALCAM clones in the absence of PMA although
this was not matched by a comparable increase in c-
Mpl expression (Figure 6B). The level of mRNA for the
erythroid genes glycophorin A and g-globin was signifi-
cantly reduced in K562-ALCAM clones compared to
K652 control at baseline (Figure 6C). As expected PMA
increased mRNA level of megakaryocytic genes and con-
comitantly decreased erythroid gene expression in the
various K562 clones (Figure 6B, C). In agreement with
our findings at steady-state, c-Mpl expression in K562-
ALCAM clones did not increase beyond the level of
control K562 cells following induction with PMA. Dis-
cordant expression of CD61 and c-Mpl reinforced the
notion that megakaryocytic differentiation in the K562-
ALCAM clones was likely dysregulated.
Apoptosis of K562-ALCAM clones undergoing
megakaryocytic differentiation
K562 cells treated with PMA are well known to display
multiple characteristic of megakaryocytic differentiation.
To further investigate the impact of ALCAM on K562
cells, we examined cells treated with PMA for the
morphological modifications that characterize megakar-
yocytic differentiation. Cells stained with May-Grun-
wald-Giemsa revealed that control K562 cells displayed
multiple phenotypes consistent with megakaryocytic dif-
ferentiation, including cell enlargement and extensive
vacuolation (Figure 7A, lower panel, arrow). On the
contrary, cultures of K562-ALCAM treated with PMA
were predominated by amorphous nuclear remnants
devoid of recognizable cytoplasm (arrow heads). Other
cell types in the K562-ALCAM cultures were markedly
smaller with condensed chromatin, and fragmented
nucleus consistent with apoptosis (Figure 7A, asterisk).
Apoptosis in K562-ALCAM clones was confirmed first,
by determining the proportion of cells at the early stage
of this process, as defined by surface expression of
annexin V. At baseline, the proportion of annexin
V-positive cells was similar (10%) in cultures of K562-
ALCAM and K562 clones. However, treatment of
cultures with PMA for 24 hours increased annexin V-
positive cells exclusively among K562-ALCAM cells by
3-fold (Figure 7B). Finally, vehicle and PMA-treated
cultures were examined for degradation of DNA using
the TUNEL assay. At baseline there was no difference in
the percentage of TUNEL-positive cells in either cell
type, or in cells treated with DMSO (Figure 7C and data
not shown). Treatment with 20 nM PMA for 48 hours
increased the percentage of TUNEL-positive cells by an
average 4-fold higher in K562-ALCAM compared to
K562 cultures.
Discussion
We report that ALCAM is selectively down-regulated in
erythromegakaryocytic progenitor cell lines, and that
this phenomenon is essential for survival of K562 cells
induced to differentiate towards the megakaryocytic
lineage. Our findings suggest that erythromegakaryocytic
progenitors that escape ALCAM down regulation may
contribute to megakaryocytopenia.
ALCAM was originally thought to be a stage-specific
molecule rather than a lineage-specific marker, based on
observations that its expression was lost as avian hema-
topoietic progenitor cells proliferated and differentiated
into mature colonies of diverse lineages [24]. More
recently, it has become clear that ALCAM is expressed
by a diversity of mature leukocytes however its lineage
A
B                                                               C
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Figure 7 ALCAM promotes apoptosis of K562 cells treated with
PMA. A) Photomicrographs of control K562 (#15) and K562-ALCAM
clones (#1, #2) stained with May-Grunwald Giemsa, at steady-state
(upper panel) or following treatment with 20 nM PMA (lower panel)
for 48 hours. PMA caused enlargement and extensive vacuolation in
K562 cells (arrow) and nuclear fragments in K562-ALCAM cells
(arrow head). B) Apoptosis as determined by the expression of
Annexin V in K562 and K562-ALCAM cells at steady-state and
following treatment with PMA for 24 hours. C) Apoptosis as
determined by the TUNEL assay in K562 and K562-ALCAM cells at
steady-state and following treatment with PMA for 48 hours. Scale
bar: 50 μm.
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study show that ALCAM expression is turned off exclu-
sively in progenitor cell lines of the erythromegakaryo-
cytic lineage (Figure 1). Taken together, this suggests
that a factor controlling erythromegakaryopoiesis
silences ALCAM gene expression. GATA-1 is an excel-
lent candidate for this role given its dominant influence
on the survival and differentiation of erythroid and
megakaryocytic progenitors [25,26]. Moreover, GATA-1
acts as a gene silencer [27,28] and a lineage-determining
factor that suppresses myelomonocytic gene expression
while promoting erythroid and megakaryocytic lineage
commitment [29]. In support of this paradigm, we
f o u n dt h a tG A T A - 1i sa b u n d a n t l ye x p r e s s e di nt h e
K562 and MEG-01 cells used in this study, which lack
ALCAM expression, while it is absent in the monocytic
cells that abundantly express ALCAM (data not shown).
More specifically, we found that there is a GATA-1 cis
element in the ALCAM promoter that inhibits promoter
activity, and is bound by GATA-1 in vivo,t h u sp r o v i d -
ing additional data to support this general paradigm.
As expected, anti-ALCAM antibody inhibited cluster-
ing of K562-ALCAM clones, confirming that this phe-
nomenon is dependent on ALCAM adhesion. Corbel
et al. [18] used a similar approach to reveal the require-
ment for ALCAM adhesion in the growth of macro-
phage, granulocyte and granulocyte/macrophage
progenitors. However, anti-ALCAM antibody had no
impact on the formation of thromboblast/erythroblast
clusters, or growth of erythroid colonies derived from
BFU-progenitors [18]. This is in agreement with our
findings in wild-type K562 cells grown in media con-
taining anti-ALCAM antibody (data not shown). We
have found that the amount of ALCAM mRNA and
protein expressed in the human erythroleukemia cell
line HEL is virtually undetectable, similar to what is
reported here for K562 and MEG-01 (data not shown).
While we cannot exclude the possibility that ALCAM is
expressed by immature erythromegakaryocytic precur-
sors, ALCAM silencing in mature precursors would
facilitate their segregation from their myeloid counter-
parts that continue to express ALCAM. In this context
apoptosis would be an effective mechanism to ensure
lineage fidelity among erythromegakaryocytic precursors
that continue to express ALCAM, as demonstrated by
this study (Figure 7). That ALCAM expression is
pro-apoptotic is contrary to its protective role against
apoptosis in breast cancer cells [30]. This apparent dis-
cordance is consistent however with the notion that
ALCAM is at the crossroads of opposing phenotypes
such as adhesion and migration [31]. ALCAM may
therefore be involved in influencing the balance between
survival and apoptosis, at least, in the hematopoietic
system.
Megakaryocytic differentiation is orchestrated by mul-
tiple signaling pathways including activation of PKCε in
both CD34 hematopoietic stem cells and in K562 cells
[32]. The major trigger for this event in K562 cells is
PMA, which activates multiple PKC isoforms. Ectopic
expression of ALCAM in K562 cells activated PKC, with
functional downstream effects on cell aggregation and
gene expression, in the absence of an external agonist
(Figure 3, 4 and 5). PKC isoforms have distinctly unique
impacts on survival and apoptosis, with the conventional
isoforms, particularly PKC-a and PKC-b being pro-sur-
vival [33,34], the novel isoform, PKC-δ is primarily pro-
apoptotic [35,36], whereas PKC-ε suppress apoptosis in
most studies [37,38]. Enhanced expression of PKC-a in
K562-ALCAM clones provided an early indication of a
potentially different signaling pattern in these clones.
PKC-δ was markedly activated without a comparable
activation of the pro-survival PKC-a (Figure 5B, C).
This pattern of activation may explain the increased
apoptosis of K562-ALCAM clones in response to a sig-
nal that normally promotes differentiation towards the
megakaryocytic lineage.
Conclusions
Our data suggest, for the first time, that silencing of
ALCAM at the bi-potential erythromegakaryocytic stage
may be crucial for cell survival during megakaryocytic
differentiation.
Methods
Chemicals and antibodies
Phorbol-12-myristate-13-acetate (PMA), Chelerythrine
chloride and lipopolysaccharide were purchased from
Sigma (St Louis, MO). Monoclonal anti-ALCAM anti-
body were purchased from Novocatra Laboratories Ltd
(Novocatra, Newcastle, UK), anti-PKC isotype-specific
antibodies, anti-EF-1a from Upstate (Charlottesville,
VA), anti-GATA-1 antibodies and goat anti-mouse IgG-
HRP from Santa Cruz Biotechnology (Santa Cruz, CA).
Generation of rabbit anti-rat ALCAM antibody BRI-1
has previously been described as anti-HB2 [39,40]. BRI-
1 antiserum was purified on a protein-A column
(ImmunoPure Plus High Capacity, Pierce Biotechnology,
Inc. Rockford, IL).
Cell culture
K562 and HL-60 cells were cultured in Iscove’sM o d i -
fied Dulbecco’s Medium (IMDM) (Invitrogen, Carlsbad,
CA), supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin and streptomycin sulfate. THP-1, Jur-
kat, U-937 and MEG-01 cells were cultured in RPMI
1640 medium (ATCC, Manassas, VA) supplemented
with 10% FBS. Cells were incubated at 37°C in a humi-
dified chamber with 5% CO2. For cell cluster formation
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10
5) were seeded in 24-well plates. Affinity purified
BRI-1 antibody (10 μg/ml) or non-immune IgG or che-
lerythrine chloride (10 μM) was added to cultures and
examined 24 hours later. For disaggregation studies,
K562-ALCAM cells (2 × 10
5) were allowed to form
large aggregates over a 24-hour period in 24-well plates,
and then the cultures were gently treated with BRI-1
antibody (10 μg/ml) or a concentration range (5-20 μM)
of chelerythrine chloride. Cultures were photographed
using Olympus IX50 microscope with digital image
(Olympus Optical Co. Ltd. Japan).
Western blot analysis
Cell lysates prepared with ice-cold Cell Lysis Buffer (Cell
Signaling Technology, Beverly, MA) containing 1% tri-
ton X-100 (v/v) and supplemented with 1% protease
inhibitor cocktail (Roche, Indianapolis, IN) was clarified
by centrifugation at 13,000 rpm for 15 min at 4°C, and
soluble cell fractions harvested. Protein content in cell
lysates was measured using a Lowry protein assay
(Sigma, St Louis, MO). Lysates were combined with buf-
fer (Sigma, St Louis), boiled for 2 min and resolved by
electrophoresis on a 10% polyacrylamide gel. Samples
were blotted unto nitrocellulose membranes, probed
with antibodies. The protein bands were identified by
chemiluminescence (Fujifilm, Japan).
Quantitative RT-PCR
Total RNA was extracted from cultured cells using
RNeasy Mini Kit (Qiagen, Valencia, CA), and converted
to cDNA using SuperScript RT II (Invitrogen,). Quanti-
tative RT-PCR was performed using gene-specific pri-
mers (Table 1), in reactions containing SYBR Green
PCR master mixture (Applied Biosystems, Foster City,
CA), on a StepOnePlus analyzer (Applied Biosystems).
Relative expression level of target genes was normalized
using GAPDH mRNA.
Stable K562 cells expressing ALCAM
We have previously described the cloning of rat
ALCAM-GFP [19]. Super coiled plasmid DNA (2.5 μg)
of ALCAM-GFP or GFP was transfected into log-phase
growing K562 cells using lipofectamine 2000 (Invitro-
gen). Stable lines were selected with G418 (1200 μg/ml)
for 20 days. Expression of ALCAM-GFP and GFP was
examined by epifluorescence (Nikon TE2000, Nikon
Instruments Inc., Melville, NY).
Reporter constructs and Site-directed mutagenesis
Human genomic DNA was amplified by PCR using a
common reverse primer complimentary to DNA
sequence 60 base pairs (bp) upstream of the translation
start site in the ALCAM gene, and various forward pri-
mers truncated at -1200, -1000, -800, -650, -400 and
Table 1 Sequence of Primers and DNA probes
ALCAM Luc reporter constructs Forward Reverse
-1200 5’-AAATCACCGCTTAACTCAAAG-3’ 5’-CCTCCTCCTTCTTGGTGG-3’
-1000 5’-CCGCGCTTCAACCACCTGCT-3’
-800 5’-CAGAAAGTGTTAGTCCCAGG-3’
-650 5’-CCGCGCTTCAACCACCTGCT-3’
-400 5’-CCGCCTCCTGCGAGTCCTTC-3’
-200 5’-GTTGACCGGGAGGGAGGAGG-3’
EMSA probes Sense strand
- 850 GATA-1 wt 5’-GCCAGAGGCCTTATCACTGG-3’
- 850 GATA-1 mt 5’-GCCAGAGGCCTGCTCACTGG-3’
ChIP assay Forward Reverse
GATA-1 5’-GGGTGGAGGGAGAGGGCAGTC-3’ 5’-AAGCAAGCACAGGAGCCGCGC-3’
RT-PCR Forward Reverse
ALCAM 5’-AGTCTT CAT TATCAGGATGC-3’ 5’-GGGATCAGTTTTCTTTGTCA-3’
g-globin 5’-ACTCGCTTCTGGAACGTCTGA-3’ 5’-GTATCTGGAGGACAGGGCACT-3’
Glycophorin A 5’-GGAATTCCAGCTCATGATCTCAGGATG-3’ 5’-TCCACATTTGGTTTGGTGAACAGAT3’
Cmpl 5’-GCACTGTGATGCTTTATGCAAC-3’ 5’-TGAACGGTTTAGAGGATGAGGA-3’
CD44 5’-GATCCACCCCAATTCCATCTGTGC-3’ 5’-AACCGCGAGAATCAAAGCCAAGGC-3’
CD61 5’-TATAGCATTGGACGGAAGGC-3’ 5’-GACCTCATTGTTGAGGCAGG-3’
GAPDH 5’-ATGGGGAAGGTGAAGGTCGG-3’ 5’-GACGGTGCCATGGAATTTGC-3’
PKCa 5’-CGAGGAAGGAAACATGGAACTCAG-3’ 5’-CCTGTCGGCAAGCATCACCTTT-3’
PKCε 5’-TCAATGGCCTTCTTAAGATCAAAA-3’ 5’-CCTGAGAGATCGATGATCACATAC-3’
PKCθ 5’-CTCGTCAAAGAGTATGTCGAATCA-3’ 5’-AATTCATTCAGTCCTTTGTGTCACTC-3’
PKCδ 5’-GCATCGCCTTCAACTCCTATGAGCT-3’ 5’-ACACACCCACGGTCACCTCAGA-3’
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into a promoter-less luciferase vector pGL3B (Promega,
Madison, WI) via Kpn Ia n dSma I cleavage sites.
The ALCAM-luciferase vectors (p1200ALCAMLuc,
p1000ALCAMLuc, p800ALCAMLuc, p650ALCAMLuc,
p400ALCAMLuc and p200ALCAMLuc) were generated
and verified by sequence analysis. Two bp substitutions
were generated in the GATA-1 binding site at -850
(CCTTATCACT®CCTGCTCACT) by site-directed
mutagenesis (QuikChange, Stratagene, La Jolla, CA), and
verified by DNA sequencing.
Reporter gene assays
Cells (2 × 10
5) were seeded in 24-well tissue culture
plates and co-transfected with ALCAM promoter luci-
ferase plasmids (800 ng) and pcDNA3.1/His/LacZ (100
ng) (Invitrogen) plasmid DNA using lipofectamine 2000.
Twenty-four hours after transfection, cell lysates were
prepared and the activities of luciferase (Firefly-Lucifer-
ase Reporter Assay System, Promega ) and b-galactosi-
dase (Galacto-Star system, Applied Biosystems) were
determined using the Veritas Luminometer (Turner Bio-
systems, Sunnyvale, CA). Luciferase activity was normal-
ized to the activity of b-galactosidase, and the relative
luciferase activity for test constructs calculated by
assigning the normalized luciferase activity of the pro-
moter-less pGL3 construct as 1.0.
Electrophoretic mobility shift assay (EMSA)
In vitro protein-DNA interaction was examined using the
LightShift Chemiluminescence electrophoretic mobility
shift assay (EMSA) kit (Pierce, Rockford, IL). ALCAM-
specific EMSA DNA probes were synthesized, gel purified
and biotin labeled (Table 1) (Integrated DNA Technolo-
gies, Coralville, IA). Nuclear extract (4 μg) was combined
with biotin-labeled DNA probes in binding buffer contain-
ing 50 μg/ml poly(dI-dC). Molar excess (50-200-fold) of
unlabelled DNA probe or anti-GATA-1 antibody (2 μg)
(Santa Cruz Biotechnology) was added to the binding
reaction in competition experiments. Products of the bind-
ing reaction were resolved in 6% DNA retardation gel
(Invitrogen), transferred to a nylon membrane and biotin-
labeled complexes detected by chemiluminescence (Fuji-
film LAS-1000 imaging system, Valhalla, NY).
Chromatin immunoprecipitation assay (ChIP)
For ChIP assay, protein-DNA cross-linking was per-
formed by fixing 40 million cells with 1% formaldehyde.
Nuclei were sonicated on ice in shearing buffer (ChIP-
IT, Active Motif, Carlsbad, CA) to obtain chromatin
fragments of 1000-100 base pairs, which were pre-
cleared with protein G beads (Salmon sperm DNA/Pro-
tein G agarose). Alternatively, pre-cleared chromatin
was incubated with anti-GATA-1 (Santa Cruz Biotech-
nology), anti-GAPD or non-immune IgG. Immune com-
plexes were precipitated with protein G beads, and the
eluate reversed cross-linked in 190 mM NaCl. DNA was
purified by centrifugation on a mini-column and ampli-
fied by PCR with specific ALCAM primers (Table 1).
PCR products were resolved by electrophoresis in 2%
agarose gels, visualized by ultraviolet illumination and
digital images recorded using GeneFlash gel documenta-
tion system (SynGene, Frederick, MD).
Apoptosis and TUNEL assays
Cells (1 × 10
6) were plated in 6-well plates and incu-
bated with PMA (20 nM) or vehicle (DMSO). Twenty-
four hours later, cells were stained with phycoerythrin
(PE) labeled annexin V and 7-Amino-actinomycin
(7-ADD), using the Apoptosis Detection kit (BD Bios-
ciences, San Jose, CA). Cells were then analyzed by
flow cytometry (FACScan Advantage, BD Biosciences)
and data from 10,000 events collected for analysis. For
the TUNEL (terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end labeling)
assay, cells (1 × 10
6) were plated in 6-well plates, and
treated for 48 hours with PMA (20 nM) or vehicle
(DMSO). Cells were fixed using freshly diluted 1% par-
aformaldehyde in PBS for 10 minutes at room temp.
Cell monolayers were prepared by cytospin on a sila-
nized microscope slide, apoptotic cells were identified
using the in situ ApopTag Peroxidase kit (Chemicon
International, Temecula, CA). Methyl green solution
(0.5%) was used to counter-stain the slides. Apoptotic
cells were counted in 10 random fields using 20×
microscope objective and the percentage TUNEL-posi-
tive cells calculated.
Statistics
Data were analyzed using GraphPad Prism software (ver-
sion 5). Student’s t-test was used to measure differences in
samples of two groups. Probability of less than 0.05 was
considered statistically significant. Levels of significance
are: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
List of abbreviations used
ALCAM: activated leukocyte cell adhesion molecule; RACE: rapid
amplification of cDNA ends; EMSA: Electrophoretic mobility shift assay; CHiP:
Chromatin immunoprecipitation assay.
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